Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ARTS-021 + Carboplatin |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ARTS-021 | ARTS 021|ARTS021 | CDK2 Inhibitor 30 | ARTS-021 is a CDK2 inhibitor, which potentially decreases tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 2568). | |
Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05867251 | Phase Ib/II | ARTS-021 + Fulvestrant + Palbociclib ARTS-021 + Letrozole + Palbociclib ARTS-021 + Carboplatin ARTS-021 | Study of ARTS-021 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |